Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by StockNews.com
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday. A number of other equities analysts also recently commented on NBIX. Piper Sandler restated an “overweight” rating and issued a $160.00 price objective on shares […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday. A number of other equities analysts also recently commented on NBIX. Piper Sandler restated an “overweight” rating and issued a $160.00 price objective on shares […]
